Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial-Reference-Cited by-同舟云学术

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial

Published:2016-06 Issue:6 Volume:74 Page:1077-1085
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Deplanque Gaël,Gervais Radj,Vergnenegre Alain,Falchero Lionel,Souquet Pierre-Jean,Chavaillon Jean-Michel,Taviot Bruno,Fraboulet Ghislaine,Saal Hakim,Robert Caroline,Chosidow Olivier

Publisher

Elsevier BV

Subject

Dermatology

Reference21 articles.

1. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

2. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D'Addario;Ann Oncol,2009

3. Tarceva [summary of product characteristics]. Basel, Switzerland: Roche. 2010.

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired Non‐Infective Disorders of the Pilosebaceous Unit;Rook's Textbook of Dermatology;2024-03-19

2. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

3. A Systematic Review of Literatures: To Identify Non-Cancer Drugs Repurposed for Lung Cancer;2023-12-04

4. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27

5. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines;Anti-Cancer Drugs;2023-01-24